Evidence map›Paper›PMID 41642388›Full record

ArticleJournal of cardiovascular translational research2026

Sustained Mechanical Occlusion of the Superior Vena Cava Safely Reduces Cardiac Filling Pressures in a Preclinical Model of Heart Failure.

Peter S Natov, Lara Reyelt, Shreyas Bhave, Elena Mahmoudi, Kevin J John, Benjamin C Dellaripa, Arik Stolyarov, Xiaoying Qiao, Jerald Curran, Sathya Unudurthi and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of cardiovascular translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Peter S NatovMolecular Cardiology Research Institute, Surgical and Interventional Research Laboratories, and the Cardiovascular Center, Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA. peter.natov1@tuftsmedicine.org.ORCID 0000-0001-9200-2385
Lara ReyeltMolecular Cardiology Research Institute, Surgical and Interventional Research Laboratories, and the Cardiovascular Center, Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA.
Shreyas BhaveMolecular Cardiology Research Institute, Surgical and Interventional Research Laboratories, and the Cardiovascular Center, Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA.
Elena MahmoudiMolecular Cardiology Research Institute, Surgical and Interventional Research Laboratories, and the Cardiovascular Center, Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA.
Kevin J JohnMolecular Cardiology Research Institute, Surgical and Interventional Research Laboratories, and the Cardiovascular Center, Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA.
Benjamin C DellaripaMolecular Cardiology Research Institute, Surgical and Interventional Research Laboratories, and the Cardiovascular Center, Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA.
Arik StolyarovMolecular Cardiology Research Institute, Surgical and Interventional Research Laboratories, and the Cardiovascular Center, Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA.
Xiaoying QiaoMolecular Cardiology Research Institute, Surgical and Interventional Research Laboratories, and the Cardiovascular Center, Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA.
Jerald CurranAbiomed, Johnson & Johnson MedTech, Danvers, MA, USA.
Sathya UnudurthiAbiomed, Johnson & Johnson MedTech, Danvers, MA, USA.
Lija SwainMolecular Cardiology Research Institute, Surgical and Interventional Research Laboratories, and the Cardiovascular Center, Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA.
Navin K KapurMolecular Cardiology Research Institute, Surgical and Interventional Research Laboratories, and the Cardiovascular Center, Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA.ORCID 0000-0002-8302-6796

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Device-based therapies may augment decongestion in acute decompensated heart failure. We investigated the efficacy and safety of prolonged mechanical superior vena cava occlusion using the preCARDIA system in a swine model of heart failure. Over 6 h of preCARDIA activation, right- and left-sided filling pressures were significantly reduced. Plasma levels of the brain injury marker ubiquitin C-terminal hydrolase L1 and intracerebral arterial pressure were not significantly changed. Post-mortem evaluation did not identify gross cerebral or histologic injury. Future studies are needed to compare continuous versus cyclic preCARDIA activation and to further confirm the neurologic safety of sustained superior vena cava occlusion.

Indexed as

Heart FailureVena Cava, SuperiorVentricular Function, LeftVentricular Function, RightVentricular PressureAnimalsArterial PressureBiomarkersDisease Models, AnimalFemaleSus scrofaTime FactorsUbiquitin ThiolesteraseBiomarkersUbiquitin ThiolesteraseHeart failureHemodynamicsMechanical circulatory supportSuperior vena cava

Identifiers

PMID41642388

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.